Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Vaxcyte, Inc.

NASDAQ: PCVX · Life Sciences · 10 alerts · CIK 1649094

Share price
$61.61Close, Nov 16
Market cap
$9.75B
Shares outstanding
158.3MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Vaxcyte, Inc. filings on SEC EDGAR ↗

4:10 PM ET Form 4
Insider Selling

Vaxcyte Chief Technical Ops Officer Harpreet S. Dhaliwal Sells $1.15M of Stock

Harpreet S. Dhaliwal, Chief Technical Ops Officer, sold 17,000 shares of Vaxcyte, Inc. at $67.33 to $68.82 a share (average $67.83) in 3 transactions, worth $1.15M in total on Nov 11, 2026. Shares held after the trade: 68,085 (-0.8%).

Value
$1.15M
Shares
17,000
Average price
$67.83
Role
Chief Technical Ops Officer
Holding change
-0.8%
Trade date
Nov 11, 2026
4:52 PM ET Form 4
Insider Selling

Vaxcyte SVP, Finance & CAO Elvia Cowan Sells $183K of Stock

Elvia Cowan, SVP, Finance & CAO, sold 3,000 shares of Vaxcyte, Inc. at $60.77 to $61.55 a share (average $60.92) in 2 transactions, worth $183K in total on Nov 2, 2026. Shares held after the trade: 27,860 (-2.1%).

Value
$183K
Shares
3,000
Average price
$60.92
Role
SVP, Finance & CAO
Holding change
-2.1%
Trade date
Nov 2, 2026
4:52 PM ET Form 4
Insider Selling

Vaxcyte EVP, Chief Scientific Ofc, COO Jim Wassil Sells $137K of Stock

Jim Wassil, EVP, Chief Scientific Ofc, COO, sold 2,250 shares of Vaxcyte, Inc. at $60.78 to $61.57 a share (average $60.90) in 2 transactions, worth $137K in total on Nov 2, 2026. Shares held after the trade: 145,435 (-0.2%).

Value
$137K
Shares
2,250
Average price
$60.90
Role
EVP, Chief Scientific Ofc, COO
Holding change
-0.2%
Trade date
Nov 2, 2026
4:19 PM ET 10-Q
Financial Results

Vaxcyte Q3 2026 Results: Net Loss of $297M, Loss Widens

Vaxcyte, Inc. is a large accelerated filer in the clinical or preclinical stages of vaccine development, reporting 158,299,981 shares of common stock outstanding as of November 2, 2026. The company continues to incur significant net losses and requires substantial additional funding to advance its pneumococcal conjugate vaccine candidates and cell-free protein synthesis platform.

Key figure
Net loss $297M
4:10 PM ET 8-K
Financial Results

Vaxcyte Financial Results

Vaxcyte reported third quarter 2026 financial results and provided a business update, highlighting positive topline Phase 3 data for its VAX-31 adult pneumococcal vaccine candidate. The company strengthened its balance sheet with $1.1 billion in net proceeds from October equity and debt offerings, resulting in a pro forma cash position of approximately $3.4 billion. Vaxcyte remains on track for a planned BLA submission for VAX-31 in the first half of 2028.

Term
Q3 2026

“The positive topline results from OPUS-1 represent a significant milestone for Vaxcyte and our broad-spectrum pneumococcal conjugate vaccine (PCV) franchise. VAX-31 met all prespecified primary endpoints in this pivotal Phase 3 trial, which inaugurated a more stringent noninferiority standard, and we believe the results further support its potential best-in-class profile.”

Grant Pickering, Chief Executive Officer and Co-Founder of Vaxcyte

“Following our positive OPUS-1 results, we completed concurrent equity and convertible senior notes offerings, raising approximately $1.1 billion in net proceeds, to further strengthen our balance sheet and extend our cash runway. With approximately $3.4 billion in pro forma cash, cash equivalents and investments as of September 30, 2026, we are well positioned to support the potential U.S. commercial launch of VAX-31 for adults and advance our other key initiatives.”

Andrew Guggenhime, President and Chief Financial Officer of Vaxcyte

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.